Business Wire

Sigfox Signs A Global Partnership With Skyhook To Improve Delivery of Geolocation Services

Share

Sigfox, a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer, has announced today its partnership with Skyhook, the leading independent provider of Wi-Fi, cellular, and hybrid positioning. The collaboration is set to improve the quality and performance of existing tracking services on the Sigfox network globally, while delivering enhanced customer experience at an accessible cost.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005469/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

As part of its services, Skyhook offers Wi-Fi location solutions, which can be used on its own or as part of a larger hybrid positioning system. This software-based, power-efficient approach uses Wi-Fi, GPS/GNSS, and cellular signals to track location, and uses over 6 billion geolocated Wi-Fi access points, over 110 million geolocated cells, and 1.5 billion geolocated IP addresses for unmatched reliability and accuracy. Through its unique approach, Skyhook’s Precision Location solution is able to accurately locate connected devices anywhere in the world.

By integrating global coverage from Skyhook’s positioning services with Sigfox’s existing Atlas Wi-Fi service, companies will be able to locate their assets in indoor environments, where other positioning methods can fall short. Customers directly benefit from the integration of Skyhook services, removing the need for additional infrastructure, regardless of the size and quantity of assets.

Atlas Wi-Fi, Sigfox’s geolocation service for massive IoT applications is specifically optimized to support global supply chain and logistics applications and combines two technologies and data sources - the Sigfox network and Wi-Fi infrastructure. Accordingly, Sigfox can provide one single location service in all types of geographic environments, without GPS.

Additionally, as Wi-Fi-based location tracking consumes less battery than using GPS, this new partnership will help extend the service life of IoT tracking solutions, thus reducing maintenance costs.

Skyhook is proud to partner with Sigfox to ensure accurate location information is available regardless of whether an asset is inside a warehouse, outside in the lot or in transit. Integrating Skyhook’s technology into Sigfox’s global location platform is an important next step as Sigfox maintains its position as a recognized global leader in the IoT space,” said Craig Waggy, CEO of Skyhook.

This partnership with Skyhook will help our clients gain better visibility of their supply chains, and ultimately provide a better service to their end customers. Understanding the exact location of assets globally without the additional costs associated with new infrastructure will no doubt drive business efficiencies. We see major traction around postal, retail and automotive use cases and Skyhook will help us provide the right quality of services for these key customers,” added Benjamin Mazet, Asset Tracking Director at Sigfox.

******

About Sigfox
Sigfox is a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer. Sigfox offers a unique combination of ultra-low cost and ultra-low power solutions enabled by a single global network, owned and operated by 75 Sigfox Operators, enabling businesses to gain visibility and track their assets worldwide. With more than 19 million connected devices and 75 million messages sent a day, Sigfox helps its customers to extract data at the lowest cost of production and accelerate their digital transformation in key areas such as asset tracking and monitoring.

ISO 9001 certified and supported by a strong partner ecosystem, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore, and Tokyo.

About Skyhook
Skyhook is the worldwide independent leader in location technology, operating the world's largest independent location network, consisting of over 6 billion geolocated Wi-Fi access points, over 110 million geolocated cells, and 1.5 billion geolocated IP addresses. Skyhook processes tens of billions of location transactions, serving devices, apps, wearables, brands and advertising platforms with precise and accurate location data and intelligence. Skyhook, through its parent company Skyhook Holding, Inc., operates as a wholly owned subsidiary of Liberty Broadband Corporation. To learn more visit www.skyhook.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press Contacts

S igfox
Antoine Mège, Corporate Communications
antoine.mege@sigfox.com

Skyhook
Isolde Decker-Lucke, Marketing Manager
idecker-lucke@skyhook.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye